knowledge -WSS

knowledge

author：fashion 2025-09-30 01:01:46 - browse：1954

Alnylam headquarters — Kristoffer Tripplaar/Sipa USA/AP

The Food and Drug Administration rejected an Alnylam Pharmaceuticals’ therapy for an increasingly prevalent heart disease, the company said Monday, citing insufficient evidence that the treatment meaningfully improved patients’ lives.

Alnylam will no longer seek approval of its drug, an intravenous medicine sold as Onpattro, for people with ATTR-CM, a progressive disease that leads to heart failure if left untreated. The company is in the late stages of development of an updated version of Onpattro that can be administered through a small needle under the skin. Data from a pivotal study, expected next year, would support an FDA application for that treatment.

For Onpattro, a 12-month clinical trial found that the treatment outperformed placebo on a test of how far patients could walk over the course of six minutes, suggesting the medicine slowed down the progression of ATTR-CM. Onpattro also improved patients’ scores on a quality-of-life questionnaire compared to placebo.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： State Dept. review finds Biden bears some blame for Afghanistan failures
Next article： Roche's accidental data boosts hopes for anti

entertainment

WSS

Wegovy’s successful heart trial raises vital question about weight loss

Jack Smith previously got search warrant for Trump's Twitter, new court docs show

In same hospitals, Black patients receive fewer opioids than white patients

How to use technology to prevent future drug shortages

Methadone doses haven’t kept up in the age of fentanyl

How the first Native Hawaiian psychiatrist helped diversify medicine

focus

knowledge

focus

Medical leaders decry Supreme Court decision on affirmative action

NIH trials fail to test meaningful long Covid therapies, experts say

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

PBMs are inflating the cost of generic drugs. They must be reined in

New air purifier tech could be key to improving indoor air quality

Kellogg’s is going to war over Mexico’s nutrition label rules

Trump demands the U.S. pay no more for drugs than other countries … again

How to make over

ChatGPT in medicine: STAT answers readers' burning questions

Trans patients at the end of life deserve respect and dignity

Wikipedia

The best solution to the drug shortages problem

Q&A: Figuring out how songbirds sing may lead to better understanding of how humans learn

Hospital at home shows how to bring innovation to health care

Q&A: Figuring out how songbirds sing may lead to better understanding of how humans learn

How the first Native Hawaiian psychiatrist helped diversify medicine

The best solution to the drug shortages problem

focus

entertainment

leisure time

hotspot